Next DestiniesNext Destinies🃏All Growlithe cards
Ask about Growlithe
Growlithe #11 Pokémon card from Next Destinies

Growlithe 11/99

Next Destinies

Find this card on eBay

Affiliate link · we may earn commission

Growlithe #11 from Next Destinies currently trades at $0.76 raw, with PSA 10 copies reaching $42.95 — a 56.5x grade premium.
Current Prices (USD)
Ungraded
$0.76
PSA 7
$14.78
PSA 8
$14.78
PSA 9
$14.78
PSA 10
$42.95
ACE 10
BGS 10 Black
$280.00
CGC 10 Pristine
$47.00
Compare on eBay

Affiliate link · we may earn commission

Quick price facts

Growlithe 11/99 from Next Destinies has a current raw market value of $0.76.

Current raw value
$0.76
PSA 9 value
$14.78
PSA 10 value
$42.95
PSA 10 premium vs raw
56.5× raw
View all cards from Next Destinies
Collector Intel
56.5x
Raw → PSA 10
High-risk grade
19.4x
Raw → PSA 9
Grade multiplier

Calculated from price history, PSA population data, and market trends. Not financial advice.

Grading Calculator

Based on PSA Standard tier (~$25 USD). Assumes a perfect PSA 10 result — actual outcome depends on card condition.

⚠️ High-variance grade. PSA 10 is 57x the raw price. The expected value accounts for the realistic probability.
$1
Buy Raw
~$25
Grading Fee
PSA Standard
$43
PSA 10 Value
+$17
Best Case (PSA 10)
if you pull a 10
Grade Multiples vs Raw
PSA 9$1519.4x raw
PSA 10$4356.5x raw

Frequently asked questions

How much is Growlithe #11 from Next Destinies worth?+
Growlithe #11 from Next Destinies is currently worth Raw: $0.76, PSA 9: $14.78, PSA 10: $42.95 based on recent sold listings. Prices update daily from real eBay sales.
Is Growlithe #11 worth grading?+
The PSA 10 price of $42.95 is 56.5× the raw price of $0.76. After a ~$25 grading fee, a PSA 10 result would net approximately $42.19 — assuming the card grades a 10.
Where do PokePrices Growlithe #11 prices come from?+
Prices are tracked nightly from real sold listings on PriceCharting (raw, PSA 9 and PSA 10). PSA population data is sourced from PSA's public reports. We do not use asking prices — only confirmed sales.